Received Feb 14, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 2 | Unknown | OT |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | — | OT |
No effects reported; received the first dose at 12 months and the second dose at 15 months; This spontaneous report was received from a nurse and referred to a 15-month-old patient of unknown gender. The patient's medical history, past medications, concomitant medications and current conditions were not reported. On approximately November 2025 (reported as 12-months-old), the patient was vaccinated with the first dose of hepatitis a vaccine, inactivated (VAQTA) Suspension for injection, 1 dosage form, total (strength, route of administration, anatomical site of application, lot number and expiration date were not provided) as prophylaxis. Then on 10-Feb-2026, the patient was vaccinated with the second dose of hepatitis a vaccine, inactivated (VAQTA) Suspension for injection, at a dose of 0.5 (units not provided) (lot number: AZO10429, which had been verified to be an invalid lot number, expiry date reported as 09-Oct-2026; strength, route of administration, and anatomical site of application were not provided) as prophylaxis (Inappropriate schedule of product administration). No effects reported (No adverse event). Batch/Lot number is being requested and will be submitted if received. This is one of the two reports received from the same reporter.